Skip to main content
Home logo

User account menu

Log inSearch

Main navigation

  • Home
  • Data Sources
  • Studies
  • Institutions
  • Networks
  • What's new
  • Support
  1. Home

Subscribe to An evaluation of non-melanoma skin cancer and melanoma skin cancer rates among patients treated for moderately to severely active rheumatoid arthritis with Xeljanz® (tofacitinib citrate): A retrospective non-interventional database study of observational data embedded within Optimising Patient outcome in Australian RheumatoLogy - Quality Use of Medicines Initiative (OPAL-QUMI) (Skin cancer rates in OpaL - SOL study)

HMA-EMA Catalogues of real-world data sources and studies

Privacy

Privacy policy
Cookies
Legal notice

Contact

Contact us